Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)'s Medical Devices Advisory Committee has strongly recommended FDA approval of the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The recommendation signals the advisory committee panel's consensus.

FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

U.S. FDA advisers back approval for Guardant's blood-based cancer test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health's blood test to screen for colorectal cancer in average-risk adults. The panel meetin.

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

Joby Aviation

DALLAS--(BUSINESS WIRE)--Trinity Industries, Inc. (“Trinity” or the “Company”) today announced that it intends to offer (the “Offering”) an additional $200.0 million aggregate principal amount of its 7.750% Senior Notes due 2028 (the “Additional Notes”). Trinity intends to use the net proceeds from the Offering, if consummated, together with cash on hand and/or borrowings under its corporate revolving credit facility, to (i) finance the repayment in full of its 4.550% Senior Notes due 2024 and.

Trinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union's In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagnostic indications to identify patients who may benefit from certain targeted therapies for advanced non.

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company's Shield™ test in colorectal cancer (CRC) screening. “One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli.

Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week

Guardant Health, Inc. (NASDAQ:GH ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Helmy Eltoukhy - Chairman & Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Jack Meehan - Nephron Research Daniel Arias - Stifel Financial Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Casey Woodring - JPMorgan Doug Schenkel - Wolfe Research Operator Good afternoon and thank you for attending the Guardant Health Q1 2024 Earnings Call. My name is Kate and I will be the moderator for today's call.

Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

Guardant Health (GH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.30 per share a year ago.

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $168.5 million for the first quarter of 2024, an increase of 31% over the first quarter of 2023 Reported 46,900 tests to clinical customers and 8,450 tests to biopharmaceutical customers in the first quarter of 2024, representing increases of 20% and 37%, respectivel.

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health's leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry. These publications have profoundly impacted the oncology field, incl.

Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone

Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company's Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024. “We look forward to discussing with the FDA Advisory Committee and its panel of experts t.

FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be.

Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024

Allogene Therapeutics Inc

Air Products and Chemicals

Sendas Distribuidora SA

American Express

BYD Company Limited

BYD Co Ltd

Cooper-Standard Holdings

Camden Property

Dollar General

Delek US Hlds

EPR Properties

Graco

SPDR Gold Trust

Intuitive Surgical

Kennedy-Wilson Holdings

MicroStrategy Incorporated

Natera

Nu Holdings

Omega Healthcare Investors

Portillo's

PayPal

Rolls-Royce Holdings PLC

There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered.

Showcasing Seeking Alpha's March 2024 New Analysts

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from pred.

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Apple

Microsoft

Starting in 2014, and even more notably in 2016 as Warren Buffett himself chipped in, Apple (NASDAQ: AAPL) became the benchmark company, and investors around the world were trying to find the ‘next Apple.'

The next Nvidia? 3 stocks poised for massive growth in 2024

Etsy

Roku

It's been nearly one and a half years since ChatGPT went live, but it sure doesn't feel like it. ChatGPT has shaken up many sectors, and triggered an AI revolution.

Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.

GH can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield's strongest adherence rate, with the potential for on-par sensitivity submission within 18 months will drive adoption. Currently trading over 1.5 STD below historical discount to Exact Sciences (EXAS), their main comp.

Guardant Health: Shield Launch Could Drive Multiple Expansion

PALO ALTO, Calif.--(BUSINESS WIRE)--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects 83% of people with colorectal cancer.

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Li Auto Inc.

Walmart

While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by major indices such as the S&P 500 and the Dow Jones Industrial Average (DJIA) which have been running close to record highs with generally favorable forecasts.

Top 3 Wall Street stock picks for March

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option. Conducted by The Harris Poll, the ‘Closing the Gap: CRC Screening Insights' survey was commissioned by Guardant Health to better understand perceptions and a.

News for Guardant Health Inc Stock (GH)